On January 18, Shanghai Kehua Bio-Engineering Co., Ltd. released the 2022 annual fiscal forecast. The total revenue is expected to reach CNY 6.5 billion to 7.5 billion; the net profit attributable to shareholders of listed companies is forecastto be CNY 890 million to 1.15 billion yuan, a year-on-year increase of 4.65%-35.23%; the basic earnings per share is expected to be CNY 1.7305 to 2.2361.

During the reporting period, the company focused on strategy and main business, and gave full play to its advantages in product development and channel terminals in the field of molecular diagnostics. The sales of molecular diagnostic products in the terminal market further increased, and the revenue and net profit increased steadily. On the other hand, the company continues to improve internal refined management and implement measures such as cost control, which further improves the company's management efficiency and overall operational capabilities, providing an internal driving force for fiscal growth.

About KHB

Established in 1981, Shanghai Kehua Bio-engineering Co., Ltd (KHB) is one of the largest developers, manufacturers and marketers of in vitro diagnostic products in China. In July 2004, KHB became the first listed company in Shen Zhen Stock Exchange focused on the IVD business. The company offers a broad range of products covering three primary business segments: Diagnostic Reagents, Diagnostic Laboratory Instruments, and Evacuated Receptacles.